ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "DMARDs"

  • Abstract Number: 036 • 2020 Pediatric Rheumatology Symposium

    Medication Related Decision-Making in Parents of Children with Juvenile Idiopathic Arthritis

    Alexandra Munroe1, Adam Huber 2, Bianca Lang 3, Suzanne Ramsey 4 and Elizabeth Stringer 4, 1Dalhousie University, Halifax, Nova Scotia, Canada, 2IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, 3Dalhousie University - Halifax, Halifax, Canada, 4IWK Health Centre, Halifax, Canada

    Background/Purpose: Outcomes for juvenile idiopathic arthritis (JIA) have improved with use of disease-modifying anti-rheumatic drugs (DMARDs) and biologics. Despite this, the decision by a parent…
  • Abstract Number: 137 • 2020 Pediatric Rheumatology Symposium

    Measuring Decision Conflict in Parents of Children with Juvenile Idiopathic Arthritis When Making the Decision to Begin Disease Modifying Anti-Rheumatic Drugs or Biologic Agents

    Chelsea DeCoste1, Suzanne Ramsey 2, Adam Huber 3, Bianca Lang 4 and Elizabeth Stringer 2, 1The Hospital for Sick Children, Toronto, Canada, 2IWK Health Centre, Halifax, Canada, 3IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, 4Dalhousie University - Halifax, Halifax, Canada

    Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) and biologic agents are routinely used in the treatment of JIA and JIA-associated uveitis (JIA-AU). Parents are often fearful, however,…
  • Abstract Number: L01 • 2019 ACR/ARP Annual Meeting

    Comparative Risk of Hospitalized Serious Infection in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study

    Yinzhu Jin 1, Hemin Lee 1, Moa Lee 2, Joan Landon 3, Joseph Merola 4, Rishi Desai 5 and Seoyoung C. Kim1, 1Brigham and Women's Hospital and Harvard Medical School, Boston, 2University of North Carolina Chapel Hill, Chapel Hill, North Carolina, 3Brigham and Women's Hospital, Boston, Massachusetts, 4Harvard Medical School, Brigham and Women's Hospital, Boston, 5Brigham and Women's hospital, Boston

    Background/Purpose: The risk of serious infection when using disease-modifying antirheumatic drugs (DMARDs), including biologic drugs is one of the major concerns for psoriasis/psoriatic arthritis (PsO/PsA)…
  • Abstract Number: L08 • 2019 ACR/ARP Annual Meeting

    Tapering of Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis Patients in Sustained Remission: Results from a Randomized Controlled Trial

    Siri Lillegraven1, Nina Sundlisater 2, Anna-Birgitte Aga 3, Joe Sexton 1, Inge Christoffer Olsen 4, Hallvard Fremstad 5, Cristina Spada 6, Tor Magne Madland 7, Christian Høili 8, Gunnstein Bakland 9, Åse Lexberg 10, Inger Johanne Widding Hansen 11, Inger Myrnes Hansen 12, Hilde Haukeland 13, Maud-Kristine Aga Ljoså 14, Ellen Moholt 15, Till Uhlig 16, Daniel Solomon 17, Désirée van der Heijde 18, Tore Kvien 16 and Espen A Haavardsholm 15, 1Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, 2Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, 3Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Oslo, Norway, 4Oslo University Hospital, Oslo, Norway, 5Ålesund Hospital, Helse Møre og Romsdal, Ålesund, Norway, 6Lillehammer Hosptial for Rheumatic Diseases, Lillehammer, Norway, 7Haukeland University Hospital, Bergen, Norway, 8Hospital Østfold HF, Moss, Norway, 9University Hospital of North Norway, Tromsø, Norway, 10Drammen Hospital, Vestre Viken HF, Drammen, Norway, 11Sørlandet Hospital HF, Kristiansand, Norway, 12Helgelandssykehuset Mo i Rana, Mo i Rana, Norway, 13Martina Hansens Hospital, Bærum, Norway, 14Ålesund Hospital Helse Møre og Romsdal HF, Ålesund, Norway, 15Diakonhjemmet Hospital, Oslo, Norway, 16Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 17Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, 18Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Sustained remission is the goal of rheumatoid arthritis (RA) care, and more patients reach and maintain this state on conventional synthetic disease modifying anti-rheumatic…
  • Abstract Number: 988 • 2019 ACR/ARP Annual Meeting

    Translational Imaging of Treatment Effects for a Novel Anti-TNF-Steroid Antibody Drug Conjugate in a Rat Model of Rheumatoid Arthritis

    Bradley Hooker1, Xiaomeng Zhang 2, Todd Cole 2, Ann Tovcimak 2, Shaughn Bryant 3, Lucy Phillips 3, David Blanchard 2, Dustin Wooten 2, Qi Guo 2, Melanie Ruzek 3, Adrian Hobson 3, Michael McPherson 3, Robert Stoffel 3, Wendy Waegell 3 and Yanping Luo 2, 1AbbVie, North Chicago, IL, 2AbbVie, North Chicago, 3AbbVie, Worcester

    Background/Purpose: Rheumatoid arthritis (RA) is an inflammatory joint disease of autoimmune etiology.  If insufficiently treated, RA leads to joint damage and irreversible disability.  Although there…
  • Abstract Number: 2369 • 2019 ACR/ARP Annual Meeting

    Treatment Patterns with Disease Modifying Anti-rheumatic Drugs in United States Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis

    Rebecca Overbury1, Shaobo Pei 2, Gopi Penmetsa 3, Brian Sauer 2, Vikas Patil 2, Jodi Walker 4, Jerry Clewell 4, Kevin Douglas 4, Daniel Clegg 5, Grant Cannon 6, Ahmad Halwani 7 and Jessica Walsh 8, 1Assisstant Professor, University of Utah, Salt Lake City, UT, 2Division of Epidemiology, Department of Internal Medicine, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, 3Gopi K. Penmetsa, MD, Division of Rheumatology, Department of Internal Medicine, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, 4AbbVie Inc., Salt Lake City, UT, 5University of Utah, Salt Lake City, UT, 6Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, 7Division of Hematology, Department of Internal Medicine, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, 8Division of Rheumatology, University of Utah, Salt Lake City, UT

    Background/Purpose: Delays in treatment for inflammatory arthritis (IA) are associated with unfavorable outcomes, including impaired quality of life, irreversible joint damage, and disability. Our objective…
  • Abstract Number: 1194 • 2019 ACR/ARP Annual Meeting

    Can an MDHAQ (Multidimensional Health Assessment Questionnaire) 60-Symptom Checklist to Monitor Early Medication Outcomes (MDHAQ/MEMO60) Detect Adverse Events of High-Risk Medications?

    Sarah Abu Mehsen 1, Isabel Castrejon 1 and Theodore Pincus2, 1Rush University Medical Center, Chicago, IL, 2Division of Rheumatology, Rush University Medical Center, Chicago, IL

    Background/Purpose: Adverse events of medications have been reported to account for 5% of hospital admissions in the US, and as many as 10% in the…
  • Abstract Number: 2394 • 2019 ACR/ARP Annual Meeting

    Use and Influence of Biologic/Janus Kinase Monotherapy Among Recently Switched Rheumatoid Arthritis Patients: Results from an Annual National Patient Chart Audit

    Lynn Price1, Phil Pouliot 1 and Lauren Schmitt 1, 1Spherix Global Insights, Exton, PA

    Background/Purpose: US rheumatologists have long agreed that methotrexate (MTX) is the backbone of rheumatoid arthritis (RA) treatment, and while comfort with biologic/JAK monotherapy is growing,…
  • Abstract Number: 1334 • 2019 ACR/ARP Annual Meeting

    Patterns of Fatigue in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs

    Dalifer Freites Nuñez1, Leticia León 2, Marta Redondo 3, Cristina Vadillo Font 4, Pia Lois 5, Arkaitz Mucientes Ruiz 4, Luis Rodríguez-Rodríguez 6, Benjamín Fernández Gutiérrez 7, Juan Angel Jover Jover 4 and lydia Abasolo Alcazar 4, 1Hospital Clínico San Carlos, MADRID, Spain, 2Fundación para la Investigación Biomedica, Madrid, Madrid, Spain, 3Universidad Camilo José Ceja, Madrid, Madrid, Spain, 4HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, 5Hospital Clínico San Carlos, Madrid, Madrid, Spain, 6Fundación para la Investigación Biomedica, Madrid, Spain, 7Hospital Clínico San Carlos, Madrid

    Background/Purpose: Fatigue is one of the most frequent symptoms in patients with rheumatoid arthritis (RA), affecting more than 80% of them. The experience of fatigue…
  • Abstract Number: 2404 • 2019 ACR/ARP Annual Meeting

    Does Combined Therapy Affects Adherence in Rheumatoid Arthritis?

    Iván de Jesús Hernández-Galarza 1, Rita Pineda-Sic1, Marielva Castro-Gonzalez 1, Diana Elsa Flores-Alvarado 1, Octavio Ilizaliturri-Guerra 1, Rodolfo Uriarte-Botello 1 and Dionicio Galarza-Delgado 1, 1Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico

    Background/Purpose: Treatment adherence in Rheumatoid Arthritis (RA) patients vary from 30 to 80%. It is important to identify the associated factors to a low adherence,…
  • Abstract Number: 1340 • 2019 ACR/ARP Annual Meeting

    Patterns of Sustained Remission and Subsequent DMARD Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort

    Maria Powell1, Vivian Bykerk 2, Orit Schieir 3, Marie-France Valois 4, Susan J. Bartlett 5, Louis Bessette 6, Gilles Boire 7, Carol Hitchon 8, Edward Keystone 9, Janet Pope 10, Carter Thorne 11, Diane Tin 12 and Glen Hazlewood 1, 1University of Calgary, Calgary, AB, Canada, 2Hospital for Special Surgery, New York City, NY, 3University of Toronto Dalla Lana School of Public Health, Toronto, ON, Canada, 4McGill University, Montreal, Canada, 5McGill University, Montreal, QC, Canada, 6Laval University, Quebec City, QC, Canada, 7Sherbrooke University, Sherbrooke, QC, Canada, 8University of Manitoba, Winnipeg, Canada, 9Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, 10Western University, London, ON, Canada, 11Southlake Regional Health Centre, Newmarket, ON, Canada, 12Southlake Regional Health Centre, Newmarket, Canada

    Background/Purpose: Rheumatoid arthritis (RA) treatment emphasizes aggressive titration of disease-modifying antirheumatic drugs (DMARDs) with the goal of achieving disease remission. This often includes the use…
  • Abstract Number: 2479 • 2019 ACR/ARP Annual Meeting

    Unmet Treatment Needs in Patients with Psoriatic Arthritis

    Daniel Aletaha1, Mihalina Georgallis 2, Matthew Wallace 2, Patrick Zueger 3 and Ruth Zeidman 2, 1Medical University of Vienna, Vienna, Austria, 2Covance Market Access & Phase IV Solutions, London, United Kingdom, 3AbbVie Inc., North Chicago

    Background/Purpose: Despite significant advances in the treatment of psoriatic arthritis (PsA), disease control and remission remain a challenge. Research characterizing residual disease burden with current…
  • Abstract Number: 1380 • 2019 ACR/ARP Annual Meeting

    Patient Characteristics, Treatment Patterns, and Treatment Persistency in Biologic DMARD-Experienced Rheumatoid Arthritis Patients in a US RA Registry

    Robin Dore1, Jenya Antonova 2, Leslie Harrold 3, Lawrence Chang 2, Emily Scherer 4, Angel Cronin 5, Kelechi Emeanuru 5 and Joel Kremer 6, 1Private practice, Tustin, CA, 2Gilead Sciences, Foster City, CA, 3Corrona, LLC and University of Massachusetts Medical School, Worcester, MA, 4Corrona, LLC, Cambridge, MA, 5Corrona, LLC, Waltham, MA, 6Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY

    Background/Purpose: Multiple treatment options are available for patients with RA. ACR guidelines recommend initiating treatment with a conventional synthetic DMARD (csDMARD). If a patient fails…
  • Abstract Number: 2708 • 2019 ACR/ARP Annual Meeting

    Effect of Immunogenicity on Efficacy and Safety of Subcutaneous or Intravenous Abatacept in Pediatric Patients with Polyarticular-Course JIA: Findings from Two Phase III Trials

    Hermine Brunner1, Nikolay Tzaribachev 2, Ingrid Louw 3, Alberto Berman 4, Inmaculada Calvo Penadés 5, Jordi Antón 6, Francisco Ávila-Zapata 7, Rubèn J Cuttica 8, Gerd Horneff 9, Robert Wong 10, Mehmooda Shaikh 11, Johanna Mora 11, Marleen Nys 12, Daniel J. Lovell 13, Alberto Martini 14 and Nicolino Ruperto 15, 1Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, 3Panorama Medical Centre, Parow, South Africa, 4Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucuman, Argentina, 5Hospital Univ. La Fe, Valencia, Spain, 6Hospital Sant Joan de Déu, Barcelona, Spain, 7Star Medica Hospital, Merida, Yucatán, Mexico, 8Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, 9Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 10Bristol-Myers Squibb, Princeton, 11Bristol-Myers Squibb, Princeton, NJ, 12Bristol-Myers Squibb, Braine L’Alleud, Belgium, 13Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, 14IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, 15Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy

    Background/Purpose: Patients (pts) with polyarticular-course JIA (pJIA) may develop anti-drug antibodies (ADAs) in response to biologics.1 Presence of ADAs has been associated with treatment (tmt)…
  • Abstract Number: 1389 • 2019 ACR/ARP Annual Meeting

    Treatment Response to Biologic DMARDs in Patients with RA: A Retrospective Analysis of the RISE Registry

    Xue Han1, Joshua Bryson 1, David C Crosby 1, Michael Evans 2 and Gabriela Schmajuk 3, 1Bristol-Myers Squibb, Princeton, 2University of California San Francisco, San Francisco, 3UCSF, SFVAMC Division of Rheumatology, San Francisco, CA

    Background/Purpose: ACR guidelines recommend treatment for patients with RA based on baseline (BL) disease activity. In patients with an inadequate response to conventional synthetic DMARDs,…
  • 1
  • 2
  • 3
  • …
  • 24
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology